Re-evaluation of Medical Devices in South Korea: Scope, Triggers and Readiness

1. Key takeaways

Re-evaluation (재평가) is a safety and effectiveness review that the Ministry of Food and Drug Safety initiates ex officio for devices already on the market, based on Article 9 of the Medical Devices Act. Compared with the post-market study under Article 8, the difference lies not in content but in how the process starts: the post-market study is a deferred condition set at the time of approval, while re-evaluation is initiated by the competent authority ex officio whenever it later considers it necessary.

• The scope of review is defined in law and covers three directions: documents submitted before marketing, adverse event data accumulated after marketing, and the status of the product abroad; it also covers approval change matters relevant to safety and effectiveness. This means a company’s change history is examined together with its current state, not the current state alone.
• The point companies most need to understand: re-evaluation does not wait for the company to show obvious problems. Changes in evidence at the product-category level, regulatory actions abroad, or clusters of adverse events for the same product type can all become triggers. Passively waiting for a notice before assembling documents is handing over the initiative.

2. Legal basis

The following instruments define the authority, scope and procedures of re-evaluation.

Note: Article 9 establishes the competent authority’s evaluation powers and the scope of evaluation materials; the methods, procedures and criteria of re-evaluation are set out in Article 19 of the Enforcement Rule. The specific initiation criteria and deadlines are matters for subordinate rules, and for each case the written notice issued by the competent authority governs.

3. Expert insights

Insight 1: writing the foreign status into the review scope puts global regulatory actions inside the domestic evaluation field of view.

Article 9 includes the product’s status abroad in the evaluation scope. For Chinese manufacturers this has a special meaning: when a product is required to modify its instructions for use, issue a safety communication or adjust its indicated population in another jurisdiction, that information can well become reference material for evaluation in South Korea. GRZAN recommends treating the global compliance event ledger as an input to Korean compliance rather than keeping disconnected records in silos.

Insight 2: the change history is an evaluation subject, and documents patched up afterwards leave traces.

Approval change matters are explicitly listed as evaluation content. What cannot be remedied at short notice is the historical record itself — what was changed in which year, on what basis, and what the risk assessment concluded at the time. If the company did not retain complete technical justification records in its day-to-day change management, it will be very hard to reconstruct a convincing timeline when re-evaluation arrives.

Insight 3: cross-checking against adverse event and distribution data is a routine evaluation tool.

Article 9 requires post-market adverse event data to be examined together. The authority’s data sources are not limited to company reports; they also include the flow and inventory information in IMDIS and the adverse event report records. GRZAN’s experience is that an inconsistency between the company’s internal conclusions and those records draws deeper evaluation more readily than the severity of any single event; for the data sources see the guide on adverse event reporting obligations and deadlines.

Insight 4: the outcome of re-evaluation can land on item renewal.

If the evaluation conclusion points to safety or effectiveness problems, the impact carries into other post-market obligations. Article 49 of the Medical Devices Act clearly provides that items with serious safety or effectiveness problems are not renewed, as described in the guide on item renewal, the 5-year validity period and the first concentrated expiry window. Re-evaluation is not a stand-alone provision.

4. Practical recommendations

• Maintain a product evidence pack that can be invoked at any time. Archive separately by the three scopes established in Article 9 — pre-market documents, post-market adverse event analysis, and foreign regulatory developments — and refresh each quarter.
• Keep the technical justification record of every approval change. The final step of a change application is leaving a record of why the change was made, including the risk assessment and verification data; the value of this appears only when an evaluation comes.
• Build a global compliance event linkage mechanism. Feed EU FSCA, United States recalls and corrections, and Chinese voluntary recalls into one ledger, with a defined Korean-side evaluation action.
• Designate a single external interface. Re-evaluation notices are usually sent to the licence holder; have the licence holder receive centrally and respond with a unified position, avoiding separate answers from different manufacturer departments.
• Put re-evaluation, recall and post-market study data on the same foundation. The three share the same product and batch data; unified data definitions are the precondition for response speed, and the recall-side entry and exit points are described in the guide on medical device recalls.

5. Verification checklist

• □ Self-assessment of evaluation scope: check document completeness item by item against the three scopes of Article 9; the pre-market documents, post-market adverse event materials and foreign status materials can all be retrieved immediately.
• □ Foreign status ledger: check the registration rules and update frequency of the global compliance event ledger; it covers safety events in the major jurisdictions and marks the Korean-side evaluation conclusions.
• □ Change record completeness: sample the justification documents of approval changes over the last three years; every change is supported by a risk assessment and verification data.
• □ Data consistency: cross-check adverse event reports, IMDIS flow data and internal analyses; the three data sets share the same definitions and every discrepancy has a written explanation.
• □ External interface: check the licence holder’s receiving and response process; a single responsible person is designated and the response position is unified.
• □ Transmission of conclusions: check how evaluation conclusions are linked to item renewal conditions; identified problems have been folded into the renewal risk assessment and left no loose ends.
• □ Update timeliness: check the update date of the evidence pack; no more than one quarter before the verification date.

Regulatory information verified as of October 29, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, Korean licence holder and local testing support for the Republic of Korea. Our team manages adverse event reporting and recall coordination with MFDS, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com